Sangamo Therapeutics Inc (NASDAQ: SGMO) is 4.07% higher on its value in year-to-date trading and has touched a low of $0.29 and a high of $1.80 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The SGMO stock was last observed hovering at around $0.56 in the last trading session, with the day’s gains setting it 0.01%.
Currently trading at $0.57, the stock is -22.44% and -28.20% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.36 million and changing 0.75% at the moment leaves the stock -26.27% off its SMA200. SGMO registered -66.14% loss for a year compared to 6-month gain of 9.85%. The firm has a 50-day simple moving average (SMA 50) of $0.40 and a 200-day simple moving average (SMA200) of -$0.74.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -38.50% loss in the last 1 month and extending the period to 3 months gives it a 24.54%, and is -6.95% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.79% over the week and 13.40% over the month.
Sangamo Therapeutics Inc (SGMO) has around 405 employees, a market worth around $115.16M and $176.23M in sales. Profit margin for the company is -146.30%. Distance from 52-week low is 94.23% and -68.68% from its 52-week high. The company has generated returns on investments over the last 12 months (-221.50%).
Sangamo Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.21 with sales reaching $6.65M over the same period.The EPS is expected to grow by 66.30% this year, but quarterly earnings will post -74.00% year-over-year. Quarterly sales are estimated to shrink -95.80% in year-over-year returns.
Sangamo Therapeutics Inc (SGMO) Top Institutional Holders
173 institutions hold shares in Sangamo Therapeutics Inc (SGMO), with institutional investors hold 48.36% of the company’s shares. The shares outstanding are 203.67M, and float is at 180.11M with Short Float at 6.04%. Institutions hold 43.79% of the Float.
The top institutional shareholder in the company is Wasatch Advisors LP with over 17.05 million shares valued at $22.17 million. The investor’s holdings represent 9.63% of the SGMO Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 15.89 million shares valued at $20.66 million to account for 8.97% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 12.4 million shares representing 7.00% and valued at over $16.12 million, while Rokos Capital Management, LLP holds 3.66% of the shares totaling 6.47 million with a market value of $8.42 million.
Sangamo Therapeutics Inc (SGMO) Insider Activity
The most recent transaction is an insider sale by BIOGEN INC.,the company’s10% Owner. SEC filings show that BIOGEN INC. sold 6,000,000 shares of the company’s common stock on Sep 26 ’23 at a price of $0.50 per share for a total of $3.0 million. Following the sale, the insider now owns 17.65 million shares.
